EUVIMEDEUVIMED entdecken
Fallbericht

Peptide Receptor Radionuclide Therapy for Recurrent Olfactory Neuroblastoma After Cranioplasty for Surgical Infection: A Case Report

Hidenori Suzuki, Shoichi Haimoto, Yoshitaka Inaba, Hiroyuki Tachibana, Keisuke Takanari, Masashi Ando, Koichi Yoshizawa, Nobuhiro Hanai

Anticancer Research · 2023

DOI: 10.21873/anticanres.16778 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Anticancer Research, 2023. Verfasst von Hidenori Suzuki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan; hi.suzuki@aichi-cc.jp. Hauptthemen laut MEDLINE: Esthesioneuroblastoma, Olfactory, Nose Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Peputide receptor radionuclide therapy with 177Lu for midgut neuroendocrine metastasis has been clinically approved as a safe treatment. Unresectable metastases of olfactory neuroblastoma have shorter survival due to insufficient effective systemic treatment. CASE REPORT: Herein, we report a patient treated with peputide receptor radionuclide therapy for unresectable recurrent olfactory neusroblastoma following a rare cranial metastasectomy infection. A 50-year-old female patient with olfactory neuroblastoma of Kadish C was initially treated by skull base surgery plus postoperative radiotherapy following chemotherapy. Recurrent disease with neck and intracranial metastases was treated by four salvage surgeries. Surgical site infection following intracranial metastasectomy was treated with debridement and delayed cranioplasty. Peputide receptor radionuclide therapy was performed for unresectable multiple metastases after cranioplasty. Successful therapy using four cycles of peputide receptor radionuclide had neither grade 3 nor grade 4 adverse events. The patient was followed at an outpatient clinic. CONCLUSION: Further case accrual of peputide receptor radionuclide therapy is required to develop a treatment for unresectable olfactory neuroblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esthesioneuroblastoma, OlfactoryNose NeoplasmsFemaleHumansMiddle AgedNasal CavityTreatment OutcomeReceptors, Peptide

Stichwörter der Autor:innen

Peputide receptor radionuclide therapycranioplastyrecurrent olfactory neuroblastomasurgical site infection

Substanzen

Receptors, Peptide

Autor:innen und Institutionen

  • Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan; hi.suzuki@aichi-cc.jp.
  • Department of Neurosurgery, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Diagnostic Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Plastic and Reconstructive Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

Zitieren

APA

Suzuki, H., Haimoto, S., Inaba, Y., Tachibana, H., Takanari, K., Ando, M., Yoshizawa, K., & Hanai, N. (2023). Peptide Receptor Radionuclide Therapy for Recurrent Olfactory Neuroblastoma After Cranioplasty for Surgical Infection: A Case Report. Anticancer Research. https://doi.org/10.21873/anticanres.16778

Vancouver

Suzuki H, Haimoto S, Inaba Y, Tachibana H, Takanari K, Ando M, et al. Peptide Receptor Radionuclide Therapy for Recurrent Olfactory Neuroblastoma After Cranioplasty for Surgical Infection: A Case Report. Anticancer Research. 2023. doi:10.21873/anticanres.16778

BibTeX
@article{Suzuki2023,
  author = {Suzuki, Hidenori and Haimoto, Shoichi and Inaba, Yoshitaka and Tachibana, Hiroyuki and Takanari, Keisuke and Ando, Masashi and Yoshizawa, Koichi and Hanai, Nobuhiro},
  title = {Peptide Receptor Radionuclide Therapy for Recurrent Olfactory Neuroblastoma After Cranioplasty for Surgical Infection: A Case Report},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16778}
}
Kostenlos starten →